text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제 66기 3분기 연결재무정보 및 재무정보는 외부감사인의 감사(검토)를 받지 아니한 것 입니다.\n요약연결재무정보\n국제약품(주) 및 종속기업 \xa0\xa0\n(단위 : 원)\n구 분\n제66기 3분기\n제65기\n제64기\n[유동자산]\n53,648,870,720\n48,535,452,258\n48,197,308,387\n-현금및현금성자산\n10,142,987,198\n5,538,928,478\n7,866,062,183\n-매출채권\n18,931,454,314\n19,131,334,053\n20,652,657,728\n-재고자산\n21,639,901,181\n22,235,167,103\n16,540,406,112\n-기타유동자산\n2,934,528,027\n1,630,022,624\n3,138,182,364\n[비유동자산]\n84,889,202,616\xa0\n88,057,410,548\xa0\n91,585,738,297\n-유형자산\n74,883,877,243\xa0\n76,828,012,026\xa0\n80,044,733,529\n-무형자산\n948,935,577\xa0\n1,125,437,214\xa0\n1,333,272,730\n-투자부동산\n3,321,920,894\xa0\n3,444,971,576\xa0\n3,354,393,245\n-기타비유동자산\n5,734,468,902\xa0\n6,658,989,732\xa0\n6,853,338,793\n자산총계\n138,538,073,336\xa0\n136,592,862,806\xa0\n139,783,046,684\n[유동부채]\n57,881,362,776\xa0\n47,855,143,190\xa0\n54,516,684,923\n[비유동부채]\n14,637,136,170\xa0\n14,658,459,606\xa0\n16,678,553,018\n부채총계\n72,518,498,946\xa0\n62,513,602,796\xa0\n71,195,237,941\n[자본금]\n21,159,832,000\xa0\n20,195,149,000\xa0\n19,276,090,000\n[주식발행초과금]\n1,112,256,192\xa0\n2,076,939,192\xa0\n2,995,998,192\n[기타포괄손익누계액]\n29,834,203,414\xa0\n29,768,646,556\xa0\n29,430,639,780\n[기타자본항목]\n15,675,311,051\xa0\n15,706,379,971\xa0\n15,770,814,508\n[이익잉여금]\n(1,768,181,940)\n6,326,958,321\xa0\n1,094,519,493\n지배기업소유주지분\n66,013,420,717\xa0\n74,074,073,040\xa0\n68,568,061,973\n비지배지분\n6,153,673\xa0\n5,186,970\xa0\n19,746,770\n자본총계\n66,019,574,390\xa0\n74,079,260,010\xa0\n68,587,808,743\n부채와자본총계\n138,538,073,336\xa0\n136,592,862,806\xa0\n139,783,046,684\n매출액\n100,076,362,214\xa0\n126,583,402,933\xa0\n119,745,568,736\n영업이익(손실)\n(573,431,466)\n5,272,527,164\xa0\n(1,675,903,581)\n당기순이익(손실)\n(8,025,072,347)\n3,542,773,665\xa0\n(1,555,791,280)\n\xa01.지배기업소유주지분\n(8,026,039,050)\n3,557,333,465\xa0\n(1,559,131,377)\n\xa02.비지배지분\n966,703\xa0\n(14,559,800)\n3,340,097\n기타포괄손익\n(3,544,353)\n2,012,502,512\xa0\n(309,724,959)\n당기총포괄손익\n(8,028,616,700)\n5,555,276,177\xa0\n(1,865,516,239)\n\xa01.지배기업소유주지분\n(8,029,583,403)\n5,569,835,977\xa0\n(1,868,856,336)\n\xa02.비지배지분\n966,703\xa0\n(14,559,800)\n3,340,097\n주당순이익(손실)\n(396)\n184\xa0\n(81)\n연결에 포함된 회사수\n1\xa0\n1\xa0\n1\n<종속기업 재무정보 요약>\n(2023년 3분기)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,679,321\n115,381\n3,008,878\n18,126\n(2022년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,549,447\n97,256\n2,992,330\n(272,996)\n(2021년) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,661,479\n370,252\n4,018,304\n62,627\n요약재무정보\n국제약품(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\n(단위 : 원)\n구 분\n제66기 3분기\n제65기\n제64기\n[유동자산]\n52,902,952,112\xa0\n47,872,340,430\xa0\n47,509,136,962\xa0\n-현금및현금성자산\n10,026,293,510\xa0\n5,309,615,691\xa0\n7,654,384,083\xa0\n-매출채권\n18,563,153,475\xa0\n18,850,395,307\xa0\n20,228,765,209\xa0\n-재고자산\n21,465,260,518\xa0\n22,078,821,355\xa0\n16,491,918,820\xa0\n-기타유동자산\n2,848,244,609\xa0\n1,633,508,077\xa0\n3,134,068,850\xa0\n[비유동자산]\n84,104,438,245\xa0\n87,116,481,391\xa0\n90,628,761,663\xa0\n-유형자산\n74,765,010,900\xa0\n76,668,342,346\xa0\n79,572,383,576\xa0\n-무형자산\n911,512,118\xa0\n1,077,738,761\xa0\n1,271,874,285\xa0\n-투자부동산\n3,191,701,327\xa0\n3,314,752,009\xa0\n3,453,461,341\xa0\n-기타비유동자산\n5,236,213,900\xa0\n6,055,648,275\xa0\n6,331,042,461\xa0\n자산총계\n137,007,390,357\xa0\n134,988,821,821\xa0\n138,137,898,625\xa0\n[유동부채]\n57,730,824,499\xa0\n47,637,353,361\xa0\n54,321,860,051\xa0\n[비유동부채]\n14,542,883,349\xa0\n14,539,844,444\xa0\n16,314,880,710\xa0\n부채총계\n72,273,707,848\xa0\n62,177,197,805\xa0\n70,636,740,761\xa0\n[자본금]\n21,159,832,000\xa0\n20,195,149,000\xa0\n19,276,090,000\xa0\n[주식발행초과금]\n1,112,256,192\xa0\n2,076,939,192\xa0\n2,995,998,192\xa0\n[기타포괄손익누계액]\n29,734,064,567\xa0\n29,668,637,929\xa0\n29,308,727,106\xa0\n[기타자본항목]\n15,848,654,978\xa0\n15,879,723,898\xa0\n15,944,158,435\xa0\n[이익잉여금]\n(3,121,125,228)\n4,991,173,997\xa0\n(23,815,869)\n자본총계\n64,733,682,509\xa0\n72,811,624,016\xa0\n67,501,157,864\xa0\n자본과부채총계\n137,007,390,357\xa0\n134,988,821,821\xa0\n138,137,898,625\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n97,067,483,911\xa0\n123,598,850,791\xa0\n115,744,739,600\xa0\n영업이익(손실)\n(626,548,507)\n5,542,738,674\xa0\n(1,747,037,562)\n당기순이익(손실)\n(8,043,198,014)\n3,339,884,503\xa0\n(1,548,270,487)\n기타포괄손익\n(3,674,573)\n2,011,200,317\xa0\n(332,931,201)\n당기총포괄손익\n(8,046,872,587)\n5,351,084,820\xa0\n(1,881,201,688)\n주당순이익(손실)\n(397)\n173\xa0\n(80)\n']"
